Cite
Toffalorio F, Santarpia M, Radice D, et al. 5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer. Oncotarget. 2018;9(23):16437-16450doi: 10.18632/oncotarget.24505.
Toffalorio, F., Santarpia, M., Radice, D., Jaramillo, C. A., Spitaleri, G., Manzotti, M., Catania, C., Jordheim, L. P., Pelosi, G., Peters, G. J., Tibaldi, C., Funel, N., Spaggiari, L., de Braud, F., De Pas, T., & Giovannetti, E. (2018). 5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer. Oncotarget, 9(23), 16437-16450. https://doi.org/10.18632/oncotarget.24505
Toffalorio, Francesca, et al. "5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer." Oncotarget vol. 9,23 (2018): 16437-16450. doi: https://doi.org/10.18632/oncotarget.24505
Toffalorio F, Santarpia M, Radice D, Jaramillo CA, Spitaleri G, Manzotti M, Catania C, Jordheim LP, Pelosi G, Peters GJ, Tibaldi C, Funel N, Spaggiari L, de Braud F, De Pas T, Giovannetti E. 5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer. Oncotarget. 2018 Feb 16;9(23):16437-16450. doi: 10.18632/oncotarget.24505. eCollection 2018 Mar 27. PMID: 29662657; PMCID: PMC5893252.
Copy
Download .nbib